Thus, we suggest that the treatment of patients with high-risk NB with anti-GD2 protocols may be improved by either eliminating or disarming TA-MSCs, choosing alternative surface targets such as CD105 [24] or targeting particular molecules or pathways that mediate their pro-tumorigenic and immune suppressive effects. The gene discussed is ENG; the disease is neuroblastoma.